Meet the Expert meeting with Prof James Larkin
Dual immunotherapy in the current treatment landscape of advanced melanoma & first line metastatic renal cell carcinoma
Expired
This course is expired
It is our pleasure to invite you to the “ Meet the expert” meeting with Prof. James Larkin.
Prof. Larkin is consultant medical oncologist at the Royal Marsden Institute in London specializing in the treatment of melanoma and cancers of the kidney. He has served as investigator for numerous clinical trials in melanoma and kidney cancer. He is the global principal investigator for CheckMate 067, which lead to the approval of dual immunotherapy for the treatment of advanced melanoma.
Professor Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 he won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the Institute of Cancer Research leading to a PhD. Specialist training was completed at The Royal Marsden and he was appointed a Consultant in 2008.
His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies.
In addition to his research interests, he runs a large advanced kidney cancer practice and one of the largest international advanced melanoma practices.
Chapters
- Prognostic and clinical factors in BRAF-V600 mutant melanoma patients for upfront dual IO therapeutic strategy
- Sequencing treatment lines for RCC patients
- Dual immunotherapy in patients with brain metastases
- Re-challenge after discontinuation for an irAE : when & how?
Panel
Prof. James Larkin
Phd, Royal Marsden Hospital London, UK
Professor James Larkin is a Consultant Medical Oncologist specializing in the treatment of melanoma and cancers of the kidney at the Royal Marsden Hospital in London.
Dr. Joseph Kerger
Senior consultant at the Institut Jules Bordet, Brussels and at CHU UCL Namur - skin and gynaecological cancers.
Prof. Dr. Sylvie Rottey
Prof. Rottey is a medical oncologist and clinical pharmacologist at UZ Gent specialized in the treatment of genitourinary and head-and-neck cancers. In addition, she leads clinical phase I-III studies and conducts research in these domains. She heads the Medical Oncology Department at UZ Gent and is head of the Drug Research Unit Ghent. She is president of BSMO (Belgian Society of Medical Oncology) and BMUC (Belgian Multidisciplinary Meeting on Urological Cancers)
ONC-BE-2100045
It is our pleasure to invite you to the “ Meet the expert” meeting with Prof. James Larkin.
Prof. Larkin is consultant medical oncologist at the Royal Marsden Institute in London specializing in the treatment of melanoma and cancers of the kidney. He has served as investigator for numerous clinical trials in melanoma and kidney cancer. He is the global principal investigator for CheckMate 067, which lead to the approval of dual immunotherapy for the treatment of advanced melanoma.
Professor Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 he won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the Institute of Cancer Research leading to a PhD. Specialist training was completed at The Royal Marsden and he was appointed a Consultant in 2008.
His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies.
In addition to his research interests, he runs a large advanced kidney cancer practice and one of the largest international advanced melanoma practices.
Chapters
- Prognostic and clinical factors in BRAF-V600 mutant melanoma patients for upfront dual IO therapeutic strategy
- Sequencing treatment lines for RCC patients
- Dual immunotherapy in patients with brain metastases
- Re-challenge after discontinuation for an irAE : when & how?